Please login to the form below

Not currently logged in
Email:
Password:

S-A in informal talks to acquire Genzyme

French drugmaker sanofi-aventis has approached Genzyme regarding a potential acquisition, according to a "reliable" source

French drugmaker sanofi-aventis (S-A) has approached Genzyme regarding a potential acquisition, according to a "reliable" source.

It is thought that S-A started informal talks with Genzyme, the largest maker of medicines for genetic diseases, about two weeks ago. The talks remain at an early stage and issues such as price and management have yet to be discussed.

Acquiring Genzyme would help S-A expand in biotechnology. Earlier this month, sources suggested S-A was planning an acquisition in the US that may be worth $20bn or more, but declined to be specific.

At the time, analysts cited Genzyme as a potential target for a takeover as well as Allegan and Biogen Idec.

Genzyme's current market capitalisation is close to $14bn.

Shares in the biotech firm climbed 21 per cent on the news of the talks, marking the largest stock price increase for Genzyme in more than a decade.

26th July 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics